AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Fragments of tubular adenoma icd 1012/31/2023 Guidelines from the UKNETwork for Neuroendocrine Tumours (Ramage et al, 2005) state that targeted radionuclide therapy, including 90Y-octreotide (also known as 90Y-DOTATOC), is a useful palliative option for symptomatic individuals with inoperable or metastatic gastroenteropancreatic neuroendocrine tumors where there is corresponding abnormally increased uptake of the corresponding radionuclide imaging agent. The gamma emitting imaging radionuclide ( 111In-octreotate) is replaced by a beta imaging therapy radionuclide (90Y-octreotide). Radiolabeled Octreotide for Therapeutic UseĪetna considers radiolabeled octreotide medically necessary for the treatment of gastroenteropancreatic neuroendocrine tumors.VIPoma (vasoactive intestinal peptide) - persons present with Verner-Morrison syndrome: watery diarrhea, hypokalemia and achlorhydria.Tumor-induced osteomalacia (oncogenic osteomalacia) (for diagnosis only). Such tumors include any of the following: Note: Technetium tc-99m pertechnetate (thallium) subtraction scan with technetium tc-99m sestamibi scan for parathyroid adenomais is considered medically necessary.Īetna considers an OctreoScan, using octreotide (Sandostatin) tagged with radiolabeled 111Indium-pentetreotide, medically necessary for the diagnosis and staging of members with primary and metastatic neuroendocrine tumors bearing somatostatin receptors. For evaluation of parathyroid adenoma.For evaluation of metastatic thyroid cancer or.For detection of malignant axillary adenopathy secondary to breast cancer or.
0 Comments
Read More
Leave a Reply. |